Introduction
============

According to the 2011 Korea National Cancer Incidence Database, the 5-year event-free survival rate of Korean children aged 0 to 14 years with cancer between 2007 and 2011 was 78.2% \[[@b1-crt-2016-197]\]. As the survival rates for childhood cancer increase, the number of survivors with long-term complications is also increasing.

One of the important late complications of cancer survivors is gonadal dysfunction. In adult survivors of childhood lymphoma, gonadal failure was reported in 11% of males and 44% of females \[[@b2-crt-2016-197]\]. In female childhood cancer survivors, the risk of premature menopause was 13.2 times higher than for their siblings (8% vs. 0.8%) \[[@b3-crt-2016-197]\]. Spermatogenesis also can be impaired in childhood cancer survivors. Specifically, applying radiation to the testes or treatment with alkylating agents are known risk factors of impaired spermatogenesis. In a recent study, azospermia was reported in 25% of childhood cancer survivors who received an alkylating agent \[[@b4-crt-2016-197]\]. Sexual dysfunction is also an important complication that can affect quality of life, but its effects have rarely been evaluated in childhood cancer survivors. Moreover, few studies have investigated both gonadal and sexual dysfunction, even though these complications tend to occur concurrently and may influence each other. Therefore, gonadal and sexual function of childhood cancer survivors were evaluated in this study.

Materials and Methods
=====================

1. Subjects
-----------

This study includes patients who visited an outpatient clinic of the Center for Pediatric Cancer of the National Cancer Center in Korea. Patients were less than 20 years old when diagnosed with cancer and were between 15 and 30 years old during the period when this study was conducted. More than 2 years had passed since the completion of therapy, and there was no evidence of recurrence. This study recruited data describing childhood cancer survivors who visited the hospital between July 2013 and February 2016. The Institutional Review Board of the National Cancer Center approved the study protocol (NCCNCS13741).

2. Procedure
------------

Demographic and medical characteristics were obtained from the patient medical records. Radiation records were also reviewed to gather data about radiation area and dose. Information regarding chemotherapy agents used for each patient was obtained from chemotherapy records. Cyclophosphamide equivalent dose (CED) was calculated according to the following formula: CED (mg/m^2^)=1.0 (cumulative cyclophosphamide dose \[mg/m^2^\])+0.244 (cumulative ifosfamide dose \[mg/m^2^\])+0.857 (cumulative procarbazine dose \[mg/m^2^\])+14.286 (cumulative chlorambucil dose \[mg/m^2^\]) +15.0 (cumulative carmustine dose \[mg/m^2^\])+16.0 (cumulative lomustine dose \[mg/m^2^\])+40 (cumulative melphalan dose \[mg/m^2^\])+50 (cumulative thiotepa dose \[mg/m^2^\])+100 (cumulative chlormethine dose \[mg/m^2^\])+8.823 (cumulative busulfan dose \[mg/m^2^\]), as suggested in a previous study \[[@b5-crt-2016-197]\].

Hormonal evaluation included follicle-stimulating hormone (FSH), luteinizing hormone (LH), and testosterone or estradiol. In females, the anti-mullerian hormone (AMH) level was also evaluated. To accomplish this, we used electrochemiluminescent immunoassay for FSH/LH, chemiluminescent immunoassay for estradiol, radioimmunoassay for testosterone, and enzyme-linked immunosorbent assay for AMH level.

Male participants collected their semen via masturbation, and samples were processed within 30 minutes of collection. As part of the analysis, semen amount and sperm concentration was checked and the morphology and motility of sperm were evaluated. Azospermia was defined as no sperm observed, and oligospermia was defined as a sperm concentration of less than 15×10^6^/mL based on the World Health Organization reference values \[[@b6-crt-2016-197]\].

3. Questionnaire
----------------

Questionnaires were presented to participants when they visited our clinic, and were returned either immediately at the clinic or later via mail. Four types of questionnaires were administered, for adolescents younger than 19 years old, adult men, adult women, and parents. Each questionnaire contained questions about quality of life and health behavior. In addition, questions about sexual function were included in questionnaires for adult men and women. Questions regarding sexual function included questions from previously validated questionnaires about male erectile function (Korean version of the International Index of Erectile Function \[IIEF-5\]) \[[@b7-crt-2016-197],[@b8-crt-2016-197]\] and about female sexual function (Korean-version of the Female Sexual Function Index \[FSFI\]) \[[@b9-crt-2016-197],[@b10-crt-2016-197]\]. Both of these questionnaires are supplied as supplementary tables ([S1](#SD1){ref-type="supplementary-material"} and [S2](#SD2){ref-type="supplementary-material"} Tables). For adolescents, questions from the 8th Korean Youth Risk Behavior Web-based Survey were used \[[@b11-crt-2016-197]\]. Survivors were also asked if they had received official sex education from a school teacher or other provider.

4. Statistical analysis
-----------------------

Demographic and treatment characteristics of participants were assessed using descriptive statistics. For comparison of continuous variables among groups, an independent t test was used. A chi-squared test and Fisher exact test were used for comparison of categorical variables. SPSS ver. 20 (IBM Corp., Armonk, NY), was used for all quantitative analyses. p-values less than 0.05 were considered significant.

Results
=======

1. Patient characteristics
--------------------------

This study included survivors who visited the hospital between July 2013 and February 2016 (n=105). Of the 105 survivors, 92 responded to the questionnaire (response rate, 78.6%). Among 61 adults, 50 replied to the questionnaire. Overall, 27 males agreed to the semen analysis.

Demographic and treatment characteristics of participants are presented in [Table 1](#t1-crt-2016-197){ref-type="table"}. CED was calculated for all patients who received an alkylating agent, except for two female patients who received chemotherapy at an outside hospital for whom information about the doses of alkylating agents could not be obtained. Semen analysis participants were older than non-participants (p=0.027), and there were no other differences between semen analysis participants and non-participants or between questionnaire responders and non-responders ([Table 1](#t1-crt-2016-197){ref-type="table"}).

2. Gonadal function of females
------------------------------

Among 48 females, 13 (27.1%) required sex hormone replacement; 10 were already receiving sex hormone therapy before our study, and three had newly started sex hormone replacement because of amenorrhoea/oligomenorrhoea due to low estradiol levels. One woman showed gonadotropin deficiency in the gonadotropin-releasing hormone (GnRH) stimulation test. The AMH level was below 1.19 ng/mL (fifth percentile cut-off value for Korean women aged 20-31) in 24 women (51.1%). Among women receiving hormone replacement, 11 (84.6%) had an AMH level less than 1.19 ng/mL. Among seven females who received stem cell transplantation, six (85.7%) received sex hormone replacement (data not shown). We divided female survivors into two groups according to median age (13.1 years), and there was no difference in gonadal function between groups. There was also no difference when the results were divided into follow-up periods of 5 years ([Table 2](#t2-crt-2016-197){ref-type="table"}).

3. Gonadal function of males
----------------------------

Among the 57 male participants, five (8.8%) had testosterone level below 325 ng/dL, suggestive of male hypogonadism ([Table 3](#t3-crt-2016-197){ref-type="table"}). Additionally, five males had testis volumes of less than 15 cm^3^. All five survivors with small testis volumes had normal testosterone levels, but four of them had azoospermia (data not shown). None of the male participants was receiving sex hormones. When divided into two groups according to median age (14.6 years), no difference in gonadal function was observed. However, when divided into follow-up durations of 5 years, all five males with testis volumes of less than 15 cm^3^ were in the group with a follow-up period of less than 5 years ([Table 3](#t3-crt-2016-197){ref-type="table"}).

Semen analysis was performed for 27 males, and azospermia and oligospermia were observed in 11 (37.5%) and three (12.5%) of the semen analysis participants, respectively. We further divided semen analysis participants into two groups according to CED (high CED \[CED ≥ 8,000 mg/m^2^\] vs. low CED \[CED \< 8,000 mg/m^2^\]). The proportion of normospermia was lower in the high CED group than in the low CED group (27.3% vs. 62.5%, p=0.047) ([Table 4](#t4-crt-2016-197){ref-type="table"}). Both males who had never used an alkylating agent showed normospermia.

4. Sexual function of survivors
-------------------------------

Sexual function of adult survivors is listed in [Table 5](#t5-crt-2016-197){ref-type="table"}. Among 50 adults, 27 males and 23 females replied to questionnaire. None of the adult survivors were married, although ten males and eight females were in a relationship. Among 10 males who had a girlfriend, two (20%) had severe erectile dysfunction (IIEF score ≤ 7) ([Table 5](#t5-crt-2016-197){ref-type="table"}). Questions regarding the FSFI are supplied in [S2 Table](#SD2){ref-type="supplementary-material"}.

Sexual function of adolescent survivors was evaluated in 25 males and 19 females. While adolescent survivors had similar experiences with sexual activity as normal high school students, six (13.6%) had not received any kind of sex education ([Table 6](#t6-crt-2016-197){ref-type="table"}).

Discussion
==========

In this study, the gonadal and sexual function of adolescent and young adult childhood cancer survivors was evaluated. Gonadal failure is classified into central hypogonadism (due to gonadotropin deficiency) and primary hypogonadism. Childhood cancer survivors are at increased risk of both central and primary hypogonadism because of radiation and chemotherapy. It is not possible to clearly distinguish central from primary hypogonadism because a GnRH stimulation test was only performed for one female in our study. However, it is believed that many patients have combined central and primary gonadal failure since 17 (16.2%) had received both brain radiation and gonadotoxic chemotherapy (data not shown).

Among female participants, 27.1% were taking sex hormones due to ovarian failure. Among female participants of the Childhood Cancer Survivor Study, acute ovarian failure was reported in 215 of 3,390 females (6.3%) \[[@b13-crt-2016-197]\], and 125 of 2,819 (4.5%) had premature ovarian failure \[[@b14-crt-2016-197]\]. Our higher prevalence of ovarian failure is partially explained by the relatively high prevalence of survivors who received alkylating agents. In previous studies, the proportion of participants who had received alkylating agents was 49.7% and 48.4%, respectively \[[@b13-crt-2016-197],[@b14-crt-2016-197]\], lower than that in our study.

AMH is used as a marker to evaluate ovarian function because it is not affected by menstrual cycle or exogenous estrogen. Although AMH is not yet recommended as a routine screening tool for gonadal function in childhood cancer survivors, it is believed to be a useful marker to evaluate ovarian reserve in female childhood cancer survivors, especially in those at risk for ovarian failure. Lunsford et al. \[[@b15-crt-2016-197]\] suggested that AMH could be the optimal screening method for assessing ovarian reserve in childhood cancer survivors.

AMH levels vary according to age, and a cut-off value has not been established. Our study used reference values for normal Korean females reported in 2011 \[[@b16-crt-2016-197]\]. Based on this reference, the AMH level was below the third percentile in 24 (51.1%) women. This cut-off value seems reasonable because 45.8% of patients (11 of 24) with an AMH below this level required hormone replacement due to amenorrhoea.

No male participants had received hormone replacement therapy. The decision to undergo sex hormone replacement may have been more difficult for men than women because there is no clinical indicator of gonadal function, such as menstruation. Testis volume can be a useful marker for gonadal function in males and is known to be related to semen profiles in normal and infertile men \[[@b17-crt-2016-197]-[@b19-crt-2016-197]\]. In our study, all males with a testis volume less than 15 cm^3^ had a follow-up period of less than 5 years, suggesting a relationship between follow-up period and testis volume. However, the number of patients was too small to evaluate the relationship between follow-up period and testis volume; therefore, a longitudinal study involving a larger number of survivors is required. In addition to symptoms directly associated with androgen deficiency, gonadal failure in males can result in an increased risk of osteoporosis and metabolic disorders \[[@b20-crt-2016-197],[@b21-crt-2016-197]\]. Therefore, we should pay special attention to the management of male hypogonadism. It is recommended that adolescent or young adult childhood cancer survivors treated with gonadotoxic therapy be monitored annually for symptoms of androgen deficiency, including decreased libido, decreased erections, and reduced testicular volume \[[@b22-crt-2016-197]\].

Risk of gonadal failure is also associated with age at diagnosis or pubertal stage at diagnosis. In females, exposure of the ovaries to chemotherapy or radiotherapy at older age was a significant risk factor for ovarian failure in a previous study \[[@b3-crt-2016-197]\]. In the present study, the prevalence of ovarian failure did not differ according to age group. However, this result can be influenced by a shorter follow up period in older age groups (6.2 years vs. 3.9 years, p=0.002), and long-term follow-up data is required to evaluate the relationship clearly. In males, radiosensitivity is higher in prepubertal boys than adult men; therefore, the testicular irradiation dose inducing Leydig cell dysfunction is lower in prepubertal subjects than males after puberty \[[@b23-crt-2016-197]\]. As a result, we assumed that more survivors who received radiation or gonadotoxic chemotherapy in the prepubertal stage had gonadal failure than those who received it at the pubertal or post-pubertal stage. The pubertal stage at diagnosis was not recorded in all patients, so we instead used the median age to divide survivors into two groups, between which no difference in prevalence of gonadal failure was observed. However, additional studies accurately examining pubertal status and investigating its relationship with gonadal function are required.

Fertility after male childhood cancer is most often evaluated based on sperm count determined by semen analysis. In the present study, half of the patients who underwent semen analysis showed azospermia or oligospermia. In a previous report that described the semen profiles of 214 adult childhood cancer survivors, azospermia or oligospermia was reported in 25% and 48% of study participants, respectively, which is similar to our findings \[[@b4-crt-2016-197]\]. In male childhood cancer survivors, chemotherapeutic agents, especially alkylating agents, surgery, or radiation to the testes, can impair spermatogenesis. Green et al. \[[@b5-crt-2016-197]\] proposed CED as an estimation of alkylating agent exposure. In another study conducted by Green et al. \[[@b4-crt-2016-197]\], CED was significantly associated with an increased risk of azospermia and oligospermia. In the present study, consistent with previous findings, azo/oligospermia was more common in the high CED group than the low CED group.

Sexual dysfunction in childhood cancer survivors can result from impairment of any process associated with sexual intercourse such as desire, erection, ejaculation, or orgasm. Surgery or irradiation (especially of the pelvis), hormonal insufficiencies, and medical comorbidities are possible etiologies of sexual dysfunction in childhood cancer survivors \[[@b24-crt-2016-197]\]. In a previous study of 282 young childhood cancer survivors, 52% of females and 32% of males had a problem in one or more areas of sexual function \[[@b25-crt-2016-197]\].

Proper sex education is required for childhood cancer survivors and their partners' health and quality of life. In our study, more than 10% of adolescent survivors had not received official sex education, indicating that strategies to provide such education are needed.

The most important aspect of our study is that we evaluated gonadal function, sexual function, and romantic relationships altogether, whereas most previous studies have investigated only of these areas. Although one previous study examined both gonadal and sexual function in childhood cancer survivors, it included only male survivors \[[@b26-crt-2016-197]\].

It should be noted that our study was limited in that the participants were uniformly young, with many in their early 20s. Additionally, none of the participants were married. Taken together, these factors may have led to underestimation of sexual function. Another limitation is that the follow-up duration after treatment was short and no longitudinal follow-up was conducted. A previous study reported that 8% of 2,819 female childhood cancer survivors experienced premature menopause before the age of 40 \[[@b4-crt-2016-197]\]. In another study that followed hematopoietic stem cell recipients (median follow-up of 7.2 years), the cumulative incidence of ovarian failure was 56% \[[@b27-crt-2016-197]\]. Longitudinal follow-up studies should be continued considering the rapid changes in treatment regimen favoring gonad protection.

Moreover, evaluation of sexual function was limited to simple questions about sexual activity, satisfaction and erectile dysfunction. Longitudinal long-term follow-up studies and more detailed investigation of other aspects of sexual function and consideration of the risk factors of sexual dysfunction should be investigated in future studies.

In conclusion, the childhood cancer survivors in this study showed a high prevalence of gonadal/sexual dysfunction. Accordingly, proper strategies for managing these complications, including appropriate sex education, should be established to improve their quality of life.
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###### 

Demographic and medical characteristics of participants

  Characteristic                                                     All patients (n=105)   Male               Female (n=48)      Adult                                                                                                           
  ------------------------------------------------------------------ ---------------------- ------------------ ------------------ ------------------------------------------------------ ------------------ ------------------ ------------------ -------
  **Age at study (yr)**                                              19.7 (15.0-26.5)       20.8 (16.0-25.7)   19.0 (15.2-26.0)   0.027^[\*](#tfn1-crt-2016-197){ref-type="table-fn"}^   19.6 (15.0-26.5)   22.0 (19.1-26.0)   21.9 (19.0-26.5)   0.883
  **Age at first diagnosis (yr)**                                    13.3 (0.9-22.6)        14.5 (7.1-19.3)    12.6 (0.9-18.9)    0.098                                                  13.0 (2.2-22.6)    15.5 (2.2-19.3)    15.5 (10.5-22.6)   0.981
  **Time since diagnosis (yr)**                                      6.5 (2.2-22.9)         6.3 (2.6-11.1)     6.4 (2.6-14.2)     0.913                                                  6.6 (2.2-22.9)     6.5 (2.5-22.9)     6.4 (3.4-10.3)     0.917
  **Time since off therapy (yr)**                                    5.2 (2.0-12.6)         5.2 (2.0-10.7)     5.4 (2.2-12.6)     0.792                                                  5.1 (2.0-10.4)     5.2 (2.0-10.7)     4.6 (2.3-10.3)     0.568
  **Sex**                                                                                                                                                                                                                                         
   Male                                                              57 (54.3)              27 (100)           30 (100)           \-                                                     \-                 27 (54.0)          5 (45.5)           0.607
   Female                                                            48 (45.7)              \-                 \-                                                                        48 (100)           23 (46.0)          6 (54.5)           
  **Diagnosis**                                                                                                                                                                                                                                   
   Leukemia                                                          23 (21.9)              5 (18.5)           4 (13.3)           0.818                                                  14 (29.2)          9 (18.0)           2 (18.2)           0.257
   Lymphoma                                                          17 (16.2)              7 (25.9)           6 (20.0)                                                                  4 (8.3)            5 (10.0)           4 (36.4)           
   Brain tumors                                                      18 (17.1)              5 (18.5)           7 (23.3)                                                                  6 (12.5)           8 (16.0)           1 (9.1)            
   Solid tumors                                                      46 (43.8)              10 (37.0)          12 (40.0)                                                                 24 (50.0)          27 (54.0)          4 (36.4)           
   Histiocytosis                                                     1 (1.0)                0                  1 (3.3)                                                                   0                  1 (2.0)            0                  
  **Alkylating agent**                                               86 (81.9)              25 (92.6)          24 (80.0)          0.258                                                  37 (77.1)          44 (88.0)          9 (81.8)           0.627
  **Stem cell transplantation**                                                                                                                                                                                                                   
   No SCT                                                            90 (85.7)              25 (92.6)          24 (80.0)          0.368                                                  \-                 44 (88.0)          9 (81.8)           0.860
   Auto PBSCT                                                        8 (7.6)                1 (3.7)            4 (13.3)                                                                  3 (6.3)            3 (6.0)            1 (9.1)            
   Allo PBSCT                                                        7 (6.7)                1 (3.7)            2 (6.7)                                                                   4 (8.3)            3 (6.0)            1 (9.1)            
  **RT**                                                                                                                                                                                                                                          
   No RT                                                             66 (62.9)              15 (55.6)          18 (60.0)          0.565                                                  33 (68.8)          31 (62)            7 (63.6)           0.401
   Cranial irradiation                                               20 (19.0)              5 (18.5)           8 (26.7)                                                                  7 (14.6)           10 (20.0)          1 (9.1)            
   TBI                                                               5 (4.8)                2 (7.4)            0                                                                         3 (6.3)            3 (6.0)            0                  
   Abdomen-pelvis RT                                                 4 (3.8)                1 (3.7)            1 (3.3)                                                                   2 (4.2)            2 (4.0)            2 (18.2)           
   Other                                                             10 (9.5)               4 (14.8)           3 (10.0)                                                                  3 (6.3)            4 (8.0)            1 (9.1)            
  **CED (mg/m^2^)^[a)](#tfn2-crt-2016-197){ref-type="table-fn"}^**                                                                                                                                                                                
   No alkylating agent                                               19 (18.4)              2 (7.4)            6 (20.0)           0.526                                                  11 (23.9)          6 (12.2)           2 (18.2)           0.939
   \< 4,000                                                          12 (11.7)              2 (7.4)            3 (10.0)                                                                  7 (15.2)           4 (8.2)            1 (9.1)            
   4,000-8,000                                                       32 (31.1)              12 (44.4)          10 (33.3)                                                                 10 (21.7)          17 (34.7)          4 (36.4)           
   ≥ 8,000                                                           40 (38.8)              11 (40.7)          11 (36.7)                                                                 18 (39.1)          22 (44.9)          4 (36.4)           

Values are presented as mean (range) or number (%). SCT, stem cell transplantation; PBSCT, peripheral blood stem cell transplantation; RT, radiation therapy; TBI, total body irradiation; CED, cyclophosphamide equivalent dose.

p \< 0.05.

Data were not available for two patients.

###### 

Gonadal function of females (n=48)

  Gonadal function                                                         All females (n=48)   Age at diagnosis (yr)   Time since off therapy (yr)                                  
  ------------------------------------------------------------------------ -------------------- ----------------------- ----------------------------- ------- ----------- ---------- -------
  Gonadotropin deficiency^[a)](#tfn3-crt-2016-197){ref-type="table-fn"}^   1                    1                       0                             \-      0           1          \-
  AMH \< 1.19 ng/mL                                                        24 (51.1)            11 (47.8)               13 (54.2)                     0.773   16 (53.3)   8 (44.4)   0.679
  Sex hormone replacement                                                  13 (27.1)            6 (25.0)                7 (29.2)                      0.745   8 (26.7)    5 (27.8)   1.000

Values are presented as number (%). AMH, anti-mullerian hormone.

Evaluated in only one patient.

###### 

Gonadal function of males

  Gonadal function                                                          All females (n=57)   Age at diagnosis (yr)   Time since off therapy (yr)                                
  ------------------------------------------------------------------------- -------------------- ----------------------- ----------------------------- ------- ---------- --------- ------------------------------------------------------
  Testosterone \< 325 ng/dL                                                 5 (8.8)              2 (7.4)                 3 (10.0)                      1.000   3 (9.7)    2 (7.7)   1.000
  Testis volume \< 15 cm^3,[a)](#tfn5-crt-2016-197){ref-type="table-fn"}^   5 (8.8)              1 (3.7)                 4 (13.3)                      0.588   5 (16.1)   0         0.026^[\*](#tfn4-crt-2016-197){ref-type="table-fn"}^
  Sex hormone replacement                                                   0                    0                       0                             \-      0          0         \-

Values are presented as number (%).

p \< 0.05.

Evaluated in 16 patients.

###### 

Semen profile

  Semen          All semen analysis participants (n=27)   CED ≥ 8,000 mg/m^2^ (n=11)   CED \< 8,000 mg/m^2^ (n=16)^[a)](#tfn6-crt-2016-197){ref-type="table-fn"}^
  -------------- ---------------------------------------- ---------------------------- ----------------------------------------------------------------------------
  Normospermia   13 (48.1)                                3 (27.3)                     10 (62.5)
  Oligospermia   3 (11.1)                                 1 (9.1)                      2 (12.5)
  Azospermia     11 (40.7)                                7 (63.6)                     4 (25)

Values are presented as number (%). CED, cyclophosphamide equivalent dose.

Including two semen analysis participants who had not received alkylating agent.

###### 

Sexual function of adult survivors (≥ 19 years)

  Variable                                                                                   Male (n=28)   Female (n=23)
  ------------------------------------------------------------------------------------------ ------------- ---------------
  **Boy/Girlfriend**                                                                         10 (35.7)     8 (34.8)
  **Married**                                                                                0             0
  **Sexual activity within the past month^[a)](#tfn7-crt-2016-197){ref-type="table-fn"}^**                 
   0-1 per week                                                                              11 (39.3)     8 (34.8)
   2-3 per week                                                                              7 (25.0)      5 (21.7)
   4-7 per week                                                                              1 (3.6)       0
   No reply                                                                                  9 (32.1)      10 (43.5)
  **Erectile dysfunction^[b)](#tfn8-crt-2016-197){ref-type="table-fn"}^**                    2 (20)        

Values are presented as number (%).

Sexual activity included not only sexual intercourse, but also kissing/caressing,

Erectile dysfunction was evaluated in 10 males who had a girlfriend.

###### 

Sexual function of adolescent survivors (15-18 years)

  Variable                                                                       Male (n=25)                                                Female (n=19)
  ------------------------------------------------------------------------------ ---------------------------------------------------------- ---------------------------------------------------------
  Experience of sexual activity^[a)](#tfn9-crt-2016-197){ref-type="table-fn"}^   3 (12.0)^[b)](#tfn10-crt-2016-197){ref-type="table-fn"}^   1 (5.3)^[b)](#tfn10-crt-2016-197){ref-type="table-fn"}^
  Experience of sex education                                                    21 (84.0)                                                  17 (89.5)

Values are presented as number (%).

Sexual activity included not only sexual intercourse, but also kissing/caressing,

Reference value for healthy high school students: 9.8% for males and 3.5% for females (from the 11th Korean Youth Risk Behavior Web-based Survey in 2015) \[[@b12-crt-2016-197]\].
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